Herpes zoster vaccine live: A 10-year review of post-marketing safety experience
Vaccine Dec 07, 2017
Willis ED, et al. - Zoster vaccine is a single dose live, attenuated vaccine (ZVL) indicated for individuals ≥50 years-old for the prevention of herpes zoster (HZ). This 10-year review of worldwide post-marketing safety experience revealed favorable safety profile of ZVL which was found to be consistent with that observed in clinical trials and post-licensure studies.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries